Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study.

Ludovini V, Chiari R, Tomassoni L, Antonini C, Baldelli E, Baglivo S, Siggillino A, Tofanetti FR, Bellezza G, Hodge KA, Petricoin E, Pierobon M, Crinò L, Bianconi F.

Oncotarget. 2017 Jun 14;8(47):83343-83353. doi: 10.18632/oncotarget.18480. eCollection 2017 Oct 10.

2.

Salvage rates and prognostic factors after relapse in children and adolescents with malignant peripheral nerve sheath tumors.

Bergamaschi L, Bisogno G, Manzitti C, D'Angelo P, Milano GM, Scagnellato A, Cappelletti M, Chiaravalli S, Dall'Igna P, Alaggio R, Ruggiero A, Di Martino M, Affinita MC, Pierobon M, Garaventa A, Casanova M, Ferrari A.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26816. Epub 2017 Sep 19.

PMID:
28926683
3.

Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.

Eke I, Makinde AY, Aryankalayil MJ, Sandfort V, Palayoor ST, Rath BH, Liotta L, Pierobon M, Petricoin EF, Brown MF, Stommel JM, Ahmed MM, Coleman CN.

Mol Cancer Ther. 2018 Feb;17(2):355-367. doi: 10.1158/1535-7163.MCT-17-0262. Epub 2017 Aug 11.

PMID:
28802252
4.

Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations.

Rao G, Pierobon M, Kim IK, Hsu WH, Deng J, Moon YW, Petricoin EF, Zhang YW, Wang Y, Giaccone G.

Sci Rep. 2017 Aug 1;7(1):7066. doi: 10.1038/s41598-017-06128-9.

5.

Winners' Cup: a national football tournament brings together adolescent patients with cancer from all over Italy.

Silva M, Chisari M, Signoroni S, Bassani A, Tagliabue L, Ricci A, Daversa M, Achini M, Spreafico F, Murelli M, Milano GM, Bisogno G, Coccoli L, Conte M, Garaventa A, Indolfi P, Perrotta S, Spinelli M, Mercolini F, Soloni P, Pierobon M, Di Cataldo A, Perillo T, Mascarin M, Coassin E, Veneroni L, Casanova M, Massimino M, Ferrari A.

Tumori. 2017 Jul 31;103(4):e25-e29. doi: 10.5301/tj.5000655.

PMID:
28665473
6.

Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.

Sereni MI, Baldelli E, Gambara G, Ravaggi A, Hodge KA, Alberts DS, Guillen-Rodriguez JM, Dong T, Memo M, Odicino F, Angioli R, Liotta LA, Pecorelli SL, Petricoin EF, Pierobon M.

Br J Cancer. 2017 Aug 8;117(4):494-502. doi: 10.1038/bjc.2017.195. Epub 2017 Jun 29.

PMID:
28664915
7.

Protein network construction using reverse phase protein array data.

Varghese RS, Zuo Y, Zhao Y, Zhang YW, Jablonski SA, Pierobon M, Petricoin EF, Ressom HW, Weiner LM.

Methods. 2017 Jul 15;124:89-99. doi: 10.1016/j.ymeth.2017.06.017. Epub 2017 Jun 24.

PMID:
28651964
8.

Reverse Phase Protein Microarrays.

Baldelli E, Calvert V, Hodge A, VanMeter A, Petricoin EF 3rd, Pierobon M.

Methods Mol Biol. 2017;1606:149-169. doi: 10.1007/978-1-4939-6990-6_11.

PMID:
28502000
9.

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF.

Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.

10.

Subthreshold linear modeling of dendritic trees: a computational approach.

Khodaei A, Pierobon M.

Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:235-238. doi: 10.1109/EMBC.2016.7590683.

PMID:
28268320
11.

Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine.

Parasido EM, Silvestri A, Canzonieri V, Belluco C, Diodoro MG, Milione M, Melotti F, De Maria R, Liotta L, Petricoin EF, Pierobon M.

Oncotarget. 2017 Jul 25;8(30):48534-48544. doi: 10.18632/oncotarget.14019.

12.

A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Pin E, Stratton S, Belluco C, Liotta L, Nagle R, Hodge KA, Deng J, Dong T, Baldelli E, Petricoin E, Pierobon M.

Mol Oncol. 2016 Dec;10(10):1585-1594. doi: 10.1016/j.molonc.2016.09.007. Epub 2016 Oct 14.

13.

Lessons from the Ebola Outbreak: Action Items for Emerging Infectious Disease Preparedness and Response.

Jacobsen KH, Aguirre AA, Bailey CL, Baranova AV, Crooks AT, Croitoru A, Delamater PL, Gupta J, Kehn-Hall K, Narayanan A, Pierobon M, Rowan KE, Schwebach JR, Seshaiyer P, Sklarew DM, Stefanidis A, Agouris P.

Ecohealth. 2016 Mar;13(1):200-12. doi: 10.1007/s10393-016-1100-5. Epub 2016 Feb 25. Review.

PMID:
26915507
14.

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF 3rd, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ.

Cancer Cell. 2016 Jan 11;29(1):75-89. doi: 10.1016/j.ccell.2015.11.011. Epub 2015 Dec 24.

15.

Phosphorylation, Signaling, and Cancer: Targets and Targeting.

Marmiroli S, Fabbro D, Miyata Y, Pierobon M, Ruzzene M.

Biomed Res Int. 2015;2015:601543. doi: 10.1155/2015/601543. Epub 2015 Oct 21. No abstract available.

16.

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.

Baldelli E, Bellezza G, Haura EB, Crinó L, Cress WD, Deng J, Ludovini V, Sidoni A, Schabath MB, Puma F, Vannucci J, Siggillino A, Liotta LA, Petricoin EF 3rd, Pierobon M.

Oncotarget. 2015 Oct 20;6(32):32368-79. doi: 10.18632/oncotarget.5941.

17.

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S.

J Clin Oncol. 2015 Dec 1;33(34):4023-31. doi: 10.1200/JCO.2015.63.2471. Epub 2015 Sep 21.

18.

Pharmacokinetic Modeling and Biodistribution Estimation Through the Molecular Communication Paradigm.

Chahibi Y, Pierobon M, Akyildiz IF.

IEEE Trans Biomed Eng. 2015 Oct;62(10):2410-20. doi: 10.1109/TBME.2015.2430011. Epub 2015 May 6.

PMID:
25955986
19.

Lung cancer prognosis before and after recurrence in a population-based setting.

Consonni D, Pierobon M, Gail MH, Rubagotti M, Rotunno M, Goldstein A, Goldin L, Lubin J, Wacholder S, Caporaso NE, Bertazzi PA, Tucker MA, Pesatori AC, Landi MT.

J Natl Cancer Inst. 2015 Mar 23;107(6):djv059. doi: 10.1093/jnci/djv059. Print 2015 Jun.

20.

Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine.

Baldelli E, Haura EB, Crinò L, Cress DW, Ludovini V, Schabath MB, Liotta LA, Petricoin EF, Pierobon M.

Proteomics Clin Appl. 2015 Oct;9(9-10):928-37. doi: 10.1002/prca.201400056. Epub 2015 Mar 24.

21.

Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy.

Sereni MI, Baldelli E, Gambara G, Deng J, Zanotti L, Bandiera E, Bignotti E, Ragnoli M, Tognon G, Ravaggi A, Meani F, Memo M, Angioli R, Liotta LA, Pecorelli SL, Petricoin E 3rd, Pierobon M.

Proteomics. 2015 Jan;15(2-3):365-73. doi: 10.1002/pmic.201400214.

PMID:
25311472
22.

A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer.

Jameson GS, Petricoin EF, Sachdev J, Liotta LA, Loesch DM, Anthony SP, Chadha MK, Wulfkuhle JD, Gallagher RI, Reeder KA, Pierobon M, Fulk MR, Cantafio NA, Dunetz B, Mikrut WD, Von Hoff DD, Robert NJ.

Breast Cancer Res Treat. 2014 Oct;147(3):579-88. doi: 10.1007/s10549-014-3117-1. Epub 2014 Sep 11.

PMID:
25209003
23.

Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab.

Pierobon M, Silvestri A, Spira A, Reeder A, Pin E, Banks S, Parasido E, Edmiston K, Liotta L, Petricoin E.

J Proteome Res. 2014 Jun 6;13(6):2846-55. doi: 10.1021/pr401267m. Epub 2014 May 14.

PMID:
24787230
24.

Application of molecular technologies for phosphoproteomic analysis of clinical samples.

Pierobon M, Wulfkuhle J, Liotta L, Petricoin E.

Oncogene. 2015 Feb 12;34(7):805-14. doi: 10.1038/onc.2014.16. Epub 2014 Mar 10. Review.

PMID:
24608425
25.

Stratification of clear cell renal cell carcinoma by signaling pathway analysis.

Cremona M, Espina V, Caccia D, Veneroni S, Colecchia M, Pierobon M, Deng J, Mueller C, Procopio G, Lanzi C, Daidone MG, Cho WC, Petricoin EF, Liotta L, Bongarzone I.

Expert Rev Proteomics. 2014 Apr;11(2):237-49. doi: 10.1586/14789450.2014.893193. Epub 2014 Feb 27.

PMID:
24575852
26.

HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.

Lai CH, Park KS, Lee DH, Alberobello AT, Raffeld M, Pierobon M, Pin E, Petricoin Iii EF, Wang Y, Giaccone G.

Oncogene. 2014 Oct 2;33(40):4867-76. doi: 10.1038/onc.2013.439. Epub 2013 Oct 28.

27.

A Molecular Communication System Model for Particulate Drug Delivery Systems.

Chahibi Y, Pierobon M, Song SO, Akyildiz IF.

IEEE Trans Biomed Eng. 2013 Dec;60(12):3468-83. doi: 10.1109/TBME.2013.2271503. Epub 2013 Jun 27.

PMID:
23807425
28.

Alcohol consumption and violence among Argentine adolescents.

Pierobon M, Barak M, Hazrati S, Jacobsen KH.

J Pediatr (Rio J). 2013 Jan-Feb;89(1):100-7. doi: 10.1016/j.jped.2013.02.015.

29.

Individualized therapy for metastatic colorectal cancer.

Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, Petricoin E, Liotta L, Belluco C.

J Intern Med. 2013 Jul;274(1):1-24. doi: 10.1111/joim.12070. Epub 2013 Apr 12. Review.

30.

Reverse phase protein microarrays and their utility in drug development.

Sereni MI, Pierobon M, Angioli R, Petricoin EF 3rd, Frederick MJ.

Methods Mol Biol. 2013;986:187-214. doi: 10.1007/978-1-62703-311-4_13.

PMID:
23436414
31.

Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis.

Pierobon M, Frankenfeld CL.

Breast Cancer Res Treat. 2013 Jan;137(1):307-14. doi: 10.1007/s10549-012-2339-3. Epub 2012 Nov 20. Review.

PMID:
23179600
32.

Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations.

Silvestri A, Calvert V, Belluco C, Lipsky M, De Maria R, Deng J, Colombatti A, De Marchi F, Nitti D, Mammano E, Liotta L, Petricoin E, Pierobon M.

Clin Exp Metastasis. 2013 Mar;30(3):309-16. doi: 10.1007/s10585-012-9538-5. Epub 2012 Sep 29.

33.

Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.

Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, DeMichele A, Walch A, Bronger H, Becker I, Waldhör C, Höfler H, Esserman L; I-SPY 1 TRIAL Investigators, Liotta LA, Becker KF, Petricoin EF 3rd.

Clin Cancer Res. 2012 Dec 1;18(23):6426-35. doi: 10.1158/1078-0432.CCR-12-0452. Epub 2012 Oct 8.

34.

Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment.

Mammano E, Galdi F, Pierobon M, Tessari E, Deng J, Pucciarelli S, Agostini M, De Marchi F, Canzonieri V, De Paoli A, Belluco C, Liotta L, Petricoin E, Pilati P, Nitti D.

Clin Colorectal Cancer. 2012 Dec;11(4):268-74. doi: 10.1016/j.clcc.2012.05.003. Epub 2012 Jun 2.

35.

Microarray data analysis: comparing two population means.

Deng J, Calvert V, Pierobon M.

Methods Mol Biol. 2012;823:325-46. doi: 10.1007/978-1-60327-216-2_21.

PMID:
22081355
36.

Reverse-phase protein microarrays.

Pierobon M, Vanmeter AJ, Moroni N, Galdi F, Petricoin EF 3rd.

Methods Mol Biol. 2012;823:215-35. doi: 10.1007/978-1-60327-216-2_14.

PMID:
22081348
37.

Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells.

Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A, Fan F, Dallas N, Xia L, Gaur P, Samuel S, Liebler DC, Ellis LM.

Br J Cancer. 2011 Nov 22;105(11):1759-67. doi: 10.1038/bjc.2011.449. Epub 2011 Nov 1.

38.

Reverse phase protein microarrays for clinical applications.

Pierobon M, Belluco C, Liotta LA, Petricoin EF 3rd.

Methods Mol Biol. 2011;785:3-12. doi: 10.1007/978-1-61779-286-1_1.

PMID:
21901589
39.

Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance?

Fodale V, Pierobon M, Liotta L, Petricoin E.

Cancer J. 2011 Mar-Apr;17(2):89-95. doi: 10.1097/PPO.0b013e318212dd3d. Review.

40.

Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV).

Younossi ZM, Limongi D, Stepanova M, Pierobon M, Afendy A, Mehta R, Baranova A, Liotta L, Petricoin E.

J Proteome Res. 2011 Feb 4;10(2):774-9. doi: 10.1021/pr100923u. Epub 2011 Jan 4.

PMID:
21204552
41.

Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing.

Silvestri A, Colombatti A, Calvert VS, Deng J, Mammano E, Belluco C, De Marchi F, Nitti D, Liotta LA, Petricoin EF, Pierobon M.

Lab Invest. 2010 May;90(5):787-96. doi: 10.1038/labinvest.2010.47. Epub 2010 Mar 1.

42.

Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker.

Pierobon M, Calvert V, Belluco C, Garaci E, Deng J, Lise M, Nitti D, Mammano E, De Marchi F, Liotta L, Petricoin E.

Clin Colorectal Cancer. 2009 Apr;8(2):110-7. doi: 10.3816/CCC.2009.n.018.

PMID:
19739273
43.

Primary stroke prevention for sickle cell disease in north-east Italy: the role of ethnic issues in establishing a Transcranial Doppler screening program.

Colombatti R, Meneghetti G, Ermani M, Pierobon M, Sainati L.

Ital J Pediatr. 2009 Jun 22;35:15. doi: 10.1186/1824-7288-35-15.

44.

Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker.

Pierobon M, Calvert V, Belluco C, Garaci E, Deng J, Lise M, Nitti D, Mammano E, Marchi FD, Liotta L, Petricoin E.

Clin Colorectal Cancer. 2009 Mar;8(2):110-7.

PMID:
19423505
45.

A portrait of tissue phosphoprotein stability in the clinical tissue procurement process.

Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S, Deng J, VanMeter AJ, Geho DH, Pastore L, Sennesh J, Petricoin EF 3rd, Liotta LA.

Mol Cell Proteomics. 2008 Oct;7(10):1998-2018. doi: 10.1074/mcp.M700596-MCP200. Epub 2008 Jul 30.

46.

Hospitalization of children with sickle cell disease in a region with increasing immigration rates.

Colombatti R, Dalla Pozza LV, Mazzucato M, Sainati L, Pierobon M, Facchin P.

Haematologica. 2008 Mar;93(3):463-4. doi: 10.3324/haematol.11766.

47.

Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.

Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D, Esserman LJ, Belluco C, Liotta LA, Petricoin EF 3rd.

J Proteome Res. 2008 Apr;7(4):1508-17. doi: 10.1021/pr7008127. Epub 2008 Feb 8.

PMID:
18257519
48.

Laser capture microdissection technology.

Espina V, Heiby M, Pierobon M, Liotta LA.

Expert Rev Mol Diagn. 2007 Sep;7(5):647-57. Review.

PMID:
17892370
49.

Reverse-phase protein microarrays: application to biomarker discovery and translational medicine.

VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF 3rd.

Expert Rev Mol Diagn. 2007 Sep;7(5):625-33. Review.

PMID:
17892368
50.

Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast.

Zavagno G, Carcoforo P, Marconato R, Franchini Z, Scalco G, Burelli P, Pietrarota P, Lise M, Mencarelli R, Capitanio G, Ballarin A, Pierobon ME, Marconato G, Nitti D.

BMC Cancer. 2005 Mar 11;5:28.

Supplemental Content

Loading ...
Support Center